Equities

Cizzle Biotechnology Holdings PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Cizzle Biotechnology Holdings PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.37
  • Today's Change0.022 / 1.63%
  • Shares traded886.62k
  • 1 Year change-31.23%
  • Beta1.0646
Data delayed at least 20 minutes, as of Feb 16 2026 12:12 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cizzle Biotechnology Holdings PLC is a United Kingdom-based diagnostics developer of early cancer tests. The Company is focused on early detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. CIZ1B is a variant of CIZ1, a naturally occurring cell nuclear protein involved in protecting deoxyribonucleic acid (DNA). Its CIZ1B biomarker detects lung cancer at its earliest and most treatable stage. It is designed as a simple blood test, which enables early diagnosis before symptoms appear-when treatment options can transform outcomes for patients and families.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-1.12m
  • Incorporated2007
  • Employees67.00
  • Location
    Cizzle Biotechnology Holdings PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
  • Phone+44 207 469 0930
  • Fax+44 238 123 0382
  • Websitehttps://cizzlebiotechnology.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Roquefort Therapeutics PLC0.00-882.45k1.80m1.00--0.3644-----0.0063-0.00630.000.03020.00----0.00-15.04---17.23-------------17.400.0747---100.00--44.29------
ValiRx Plc49.78k-1.78m2.45m14.00--0.3579--49.24-0.0094-0.00940.00020.00920.01470.000.60683,555.71-55.35-48.98-51.45-49.62100.00---3,775.95-16,086.598.87--0.0022--418.54--5.99---37.39--
N4 Pharma PLC7.07k-1.07m3.95m4.00--2.24--559.17-0.0025-0.00250.000020.00210.0045--0.07561,767.50-71.04-59.59-74.91-63.90-----15,981.33-67,987.22----0.00--273.33--16.60------
TheraCryf PLC0.00-2.01m4.51m9.00--0.9398-----0.0017-0.00170.000.00220.00----0.00-41.20-38.70-53.79-42.97-------1,407.46----0.00---100.00--38.13------
Cizzle Biotechnology Holdings PLC0.00-1.12m5.35m67.00---------0.0028-0.00280.00-0.00070.00-------190.34-146.14-433.59-169.40--------0.4766-2.42---------26.15------
OptiBiotix Health PLC1.15m-191.00k6.51m5.00--0.7729464.855.65-0.0018-0.00180.01130.08150.1341.932.88230,200.00-2.2217.23-2.3317.8445.4450.78-16.59189.343.75--0.0094.9335.093.1511.48------
Futura Medical PLC7.93m-6.29m7.53m12.00--1.29--0.9497-0.0207-0.02070.02610.011.06137.368.58---84.19-45.00-112.42-71.7970.67---79.41-108.252.21--0.00--349.09237.55119.85--121.02--
Talisman Metals PLC0.0065.21k7.68m1.00--3.21117.83---0.0064-0.0160.000.03730.00----0.003.15-30.403.64-33.15------------0.00------99.94------
IXICO PLC6.53m-1.65m8.22m79.00--0.7007--1.26-0.0186-0.01860.0730.12670.5222--3.1882,708.86-13.19-3.47-15.43-4.0348.7155.52-25.27-6.21----0.015--13.32-7.2717.49---5.30--
Genflow Biosciences PLC0.00-1.80m9.13m5.00---------0.005-0.0050.00-0.00070.00----0.00-197.92---648.46----------------------14.68------
Solvonis Therapeutics PLC0.00-2.60m17.70m----2.22-----0.001-0.0010.000.00120.00-------44.49---54.32-------------645.250.011---100.00--53.62------
Fusion Antibodies PLC1.60m-1.47m18.44m24.00--23.09--11.55-0.0144-0.01440.01520.00640.95574.961.9666,500.00-87.84-56.24-137.88-73.6722.0636.41-91.92-71.051.45-190.630.3483--72.98-12.7923.05---37.98--
Sareum Holdings Plc0.00-4.44m25.54m5.00--10.92-----0.0365-0.03650.000.01690.00----0.00-126.85-93.37-202.14-118.41------------0.00-------29.77------
Data as of Feb 16 2026. Currency figures normalised to Cizzle Biotechnology Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

0.01%Per cent of shares held by top holders
HolderShares% Held
Unicorn Asset Management Ltd.as of 31 Jan 202634.20k0.01%
Data from 31 Jan 2026 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.